SLC5A2 and liver dysplastic nodule: Currently, the therapeutic strategies that limit the development of DN include anti-hyperglycemic sodium-glucose cotransporter 2 (SGLT2) inhibitors, as well as anti-hypertensive angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) (Zhang et al., 2022a; Barrera-Chimal et al., 2022; Vergara et al., 2023).